Studies in patients with solid tumors are available for patients with both newly diagnosed and recurrent sarcomas. Front-line treatment regimens are available for patients with previously untreated Ewing's sarcoma of bone and soft tissue, PNET, rhabdomyosarcoma, and unresectable or metastatic high-grade non-rhabdomyosarcoma soft tissue sarcomas. Because standard therapy offers the potential for cure in a large percentage of patients with non-metastatic sarcomas, new therapeutic modalities have focused upon treatment for patients with metastatic and recurrent sarcomas. Current protocols for patients with newly diagnosed sarcomas utilize dose intensive chemotherapy for patients with non-metastatic sarcomas and offer a combination of dose intensive chemotherapy and tumor vaccine with T cell transplantation and interleukin-2 for eligible patients with metastatic sarcomas. Treatment regimens for patients with recurrent tumors include: an immunotherapy trial which incorporates a tumor vaccine with interleukin-2 in patients with recurrent rhabdomyosarcoma and Ewing's sarcoma family of tumors, a combination of growth factor inhibitors (Sandostatin-LAR +/-Tamoxifen) designed to reduce circulating levels of insulin-like growth factor type I (IGF-I) in patients with osteosarcoma.

See also:
Solid Tumor Protocols
Phase I Clinical Trials

Last Updated: March 10, 2003

NCI Home Page|| NIH Home Page

© 2002-2003, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute